AdoXLong Sema

AdoXLong Sema is a long-acting injectable formulation of semaglutide developed by Adocia using its proprietary AdoXLong platform technology. The platform utilizes a biocompatible polymer chemically linked to the semaglutide peptide to extend its duration of action without altering its biological mechanism. As a glucagon-like peptide-1 (GLP-1) receptor agonist, it is designed to provide sustained receptor activation for the treatment of obesity. Early results suggest the formulation is compatible with once-monthly subcutaneous administration, offering a potentially more convenient dosing schedule compared to existing weekly GLP-1 therapies. The drug is formulated as a low-viscosity aqueous solution suitable for standard injection devices.

Other names

semaglutide AdoXLonglong-acting semaglutide Adocia